We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

BioVendor Group

BioVendor Group is an international group of biotechnology companies (BioVendor LM, BioVendor R&D, TestLine, ViennaLa... read more Featured Products: More products

Download Mobile App





Biovendor Group presents its CLIA, NGS, Microblot Array, microRNA and LAMP Product Lines at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
BioVendor Group (Brno, Czech Republic) presented its CLIA, NGS, Microblot Array, microRNA and LAMP product lines at the 2021 edition of MEDICA, the world's largest trade fair for medical technology, held from 15 to 18 November in Düsseldorf, Germany.

BioVendor presented its newly-launched KleeYab fully automated analyzer, a highly flexible, fast and sensitive random access chemiluminescence platform that provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment. More...
The open platform system features a unique trigger cartridge technology that allows the use of both flash and glow detection technologies, along with unique stackable reaction cuvettes to eliminate system handling errors and reduce shipping and storage space.

BioVendor demonstrated its new Next Generation Sequencing (NGS) technology, fastGEN designed for examination of the mutation status of oncomarkers in samples. Its technology is based on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material.

At MEDICA 2021, BioVendor also demonstrated its Microblot-Array (MBA), a new generation of a market-unique immunoblot array in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which is time and cost-saving. The technology eliminates the limited capacity of traditional BLOT strips and opens the way to high throughput testing. Simple processing can be done manually or automatically using any open ELISA analyzers. Additionally, BioVendor presented its complete solution for microRNAs (miRNAs) and other short non-coding RNA sequences (sncRNA) projects, starting with isolation, followed by screening for proper targets and their final quantification. BioVendor also showcased its loop-mediated isothermal amplification (LAMP) assays which bring a novel approach for direct detection of target nucleic acids without the need of isolation step. The unique architecture of the LAMP method ensures its high sensitivity and specificity, and a tolerance for inhibitory substances.

Related Links:
BioVendor Group


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.